Key facts
- This page summarizes GOLDMAN SACHS GROUP INC's Form 3 filing for NeuroBo Pharmaceuticals, Inc. (MTVA).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 22 Nov 2022, 15:46.
GOLDMAN SACHS GROUP INC - 16 Nov 2022 Form 3 Insider Report for NeuroBo Pharmaceuticals, Inc. (MTVA)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- MTVA
- Reported as of
- 16 Nov 2022
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 22 Nov 2022, 15:46:00 UTC
- Prior SEC filing
- 17 Nov 2022
- Next SEC filing
- 21 Nov 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jamison Yardley, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
GOLDMAN SACHS GROUP INC filed Form 3 for NeuroBo Pharmaceuticals, Inc. (MTVA) on 22 Nov 2022.
Change
- Previous filing in this sequence was filed on 17 Nov 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NRBO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,220,502
- Date
- 16 Nov 2022
- Ownership
- See Footnotes
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This statement is being filed by The Goldman Sachs Group, Inc. ("GS Group") and Goldman Sachs & Co. LLC ("Goldman Sachs" and together with GS Group, the "Reporting Persons"). Goldman Sachs is a subsidiary of GS Group. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. On November 16, 2022, the Reporting Persons experienced an increase in their beneficial ownership of Neurobo Pharmaceuticals, Inc. (the "Issuer") to above 10% of the outstanding Common Stock. On November 17, 2022, the Reporting Persons experienced a decrease in their beneficial ownership that reduced their beneficial ownership to below 10% due to a reduction in excess securities borrows.
Footnote F2
The Common Stock of the Issuer reported herein as indirectly purchased were beneficially owned directly by Goldman Sachs and indirectly by GS Group.